Related content

Changes in bone health and skeletal-related events following implementation of a multidisciplinary consensus statement guiding surveillance and treatment of men undergoing androgen deprivation therapy for prostate cancer

By Nelson Dayne Matthew   Peterson Andrew Charles  

The Aging Male, Vol. 13, Iss. 2, 2010-06 ,pp. : 120-123

Informa Healthcare

Access to resources Recommend Favorite

Does primary androgen-deprivation therapy improve survival for localized prostate cancer?

By Loeb Stacy   Schaeffer Edward M  

Aging Health, Vol. 4, Iss. 5, 2008-10 ,pp. : 451-453

Future Medicine

Access to resources Recommend Favorite

Bisphosphonate therapy for the treatment of skeletal complications in patients with prostate cancer

By Harzstark Andrea L   Ryan Charles J   Small Eric J  

Aging Health, Vol. 2, Iss. 6, 2006-12 ,pp. : 943-954

Future Medicine

Access to resources Recommend Favorite

Significant associations of prostate-specific antigen nadir and time to prostate-specific antigen nadir with survival in prostate cancer patients treated with androgen-deprivation therapy

By Huang Shu-Pin   Bao Bo-Ying   Wu Ming-Tsang   Choueiri Toni K.   Goggins William B.   Liu Chia-Chu   Huang Chao-Yuan   Pu Yeong-Shiau   Yu Chia-Cheng   Wu Tony T.   Huang Chun-Nung   Huang Chun-Hsiung   Wu Wen-Jeng  

The Aging Male, Vol. 15, Iss. 1, 2012-03 ,pp. : 34-41

Informa Healthcare

Access to resources Recommend Favorite

The effect of short-term estradiol therapy on clotting and inflammatory markers in older men receiving hormonal suppression therapy for prostate cancer

By Taxel Pamela   Luthra Pooja   Fall Pamela   Dauser Deborah  

The Aging Male, Vol. 11, Iss. 2, 2008-06 ,pp. : 71-75

Informa Healthcare

Access to resources Recommend Favorite